Asset Details
Do you wish to reserve the book?
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
Do you wish to request the book?
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
2015
Overview
The new oral anticoagulants have many advantages over warfarin, but one disadvantage is the inability to rapidly reverse their anticoagulant effects. Andexanet, a small-molecule factor Xa fragment, rapidly lowered levels of rivaroxaban and apixaban in older healthy volunteers.
The direct factor Xa inhibitors apixaban, rivaroxaban, and edoxaban are used in the prevention and treatment of thromboembolism. Indications for the use of these agents include the prevention of stroke in patients with nonvalvular atrial fibrillation, the treatment and secondary prevention of deep-vein thrombosis and pulmonary embolism, and the prevention of venous thrombosis after orthopedic surgery. In spite of the demonstrated safety and efficacy of factor Xa inhibitors, as well as their practical advantages over vitamin K antagonists such as warfarin, the lack of a specific antidote to reverse their anticoagulant effects is an important limitation. In clinical trials involving . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Blood Coagulation - drug effects
/ Factor Xa Inhibitors - adverse effects
/ Factor Xa Inhibitors - therapeutic use
/ Female
/ Hemorrhage - chemically induced
/ Humans
/ Male
/ Peptide Fragments - metabolism
/ Protein Precursors - metabolism
/ Recombinant Proteins - pharmacology
/ Recombinant Proteins - therapeutic use
/ Rivaroxaban - adverse effects
/ Rivaroxaban - therapeutic use
/ Thrombin
